Overview

  • Product name
    Anti-Glucokinase antibody [EPR10374]
    See all Glucokinase primary antibodies
  • Description
    Rabbit monoclonal [EPR10374] to Glucokinase
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment corresponding to Human Glucokinase.
    Database link: P35557

  • Positive control
    • BxPC-3 lysate.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab155962 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/50000 - 1/200000. Predicted molecular weight: 52 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function
      Catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. Glucokinase has a high Km for glucose, and so it is effective only when glucose is abundant. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.
    • Tissue specificity
      Isoform 1 is expressed in pancreas. Isoform 2 and isoform 3 is expressed in liver.
    • Involvement in disease
      Defects in GCK are the cause of maturity-onset diabetes of the young type 2 (MODY2) [MIM:125851]; also shortened MODY-2. MODY is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
      Defects in GCK are the cause of familial hyperinsulinemic hypoglycemia type 3 (HHF3) [MIM:602485]; also known as persistent hyperinsulinemic hypoglycemia of infancy (PHHI) or congenital hyperinsulinism. HHF is the most common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur.
    • Sequence similarities
      Belongs to the hexokinase family.
    • Information by UniProt
    • Database links
    • Alternative names
      • ATP:D-hexose 6-phosphotransferase antibody
      • FGQTL3 antibody
      • GCK antibody
      • GK antibody
      • GLK antibody
      • Glucokinase antibody
      • Hexokinase D pancreatic isozyme antibody
      • Hexokinase type IV antibody
      • Hexokinase-4 antibody
      • Hexokinase-D antibody
      • HHF3 antibody
      • HK IV antibody
      • HK4 antibody
      • HKIV antibody
      • HXK4_HUMAN antibody
      • HXKP antibody
      • LGLK antibody
      • MODY2 antibody
      see all

    Images

    • Anti-Glucokinase antibody [EPR10374] (ab155962) at 1/50000 dilution + BxPC-3 cell lysate at 10 µg

      Secondary
      HRP labelled goat anti-rabbit
      at 1/2000 dilution

      Predicted band size: 52 kDa

    References

    ab155962 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab155962.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up